These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 31795962)

  • 1. CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy.
    Alves WEFM; Bonatelli M; Dufloth R; Kerr LM; Carrara GFA; da Costa RFA; Scapulatempo-Neto C; Tiezzi D; da Costa Vieira RA; Pinheiro C
    BMC Cancer; 2019 Dec; 19(1):1173. PubMed ID: 31795962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression.
    Pinheiro C; Sousa B; Albergaria A; Paredes J; Dufloth R; Vieira D; Schmitt F; Baltazar F
    Histol Histopathol; 2011 Oct; 26(10):1279-86. PubMed ID: 21870331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic reprogramming: a new relevant pathway in adult adrenocortical tumors.
    Pinheiro C; Granja S; Longatto-Filho A; Faria AM; Fragoso MC; Lovisolo SM; Lerário AM; Almeida MQ; Baltazar F; Zerbini MC
    Oncotarget; 2015 Dec; 6(42):44403-21. PubMed ID: 26587828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome.
    Doyen J; Trastour C; Ettore F; Peyrottes I; Toussant N; Gal J; Ilc K; Roux D; Parks SK; Ferrero JM; Pouysségur J
    Biochem Biophys Res Commun; 2014 Aug; 451(1):54-61. PubMed ID: 25058459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expression of metabolism-related proteins in phyllodes tumors.
    Kwon JE; Jung WH; Koo JS
    Tumour Biol; 2013 Feb; 34(1):115-24. PubMed ID: 22986897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer.
    Generali D; Fox SB; Berruti A; Brizzi MP; Campo L; Bonardi S; Wigfield SM; Bruzzi P; Bersiga A; Allevi G; Milani M; Aguggini S; Dogliotti L; Bottini A; Harris AL
    Endocr Relat Cancer; 2006 Sep; 13(3):921-30. PubMed ID: 16954440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline.
    Aomatsu N; Yashiro M; Kashiwagi S; Kawajiri H; Takashima T; Ohsawa M; Wakasa K; Hirakawa K
    BMC Cancer; 2014 Jun; 14():400. PubMed ID: 24893880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical importance of serum urokinase plasminogen activator receptor and carbonic anhydrase IX levels and the effect of anthracycline-based adjuvant chemotherapy on these biomarkers in breast cancer.
    Topcu TO; Ozdemir F; Kavgaci H; Gunaldi M; Kocoglu H; Imamoglu GI; Mentese A; Yaman SO; Orem A; Aydin F
    J Cancer Res Ther; 2018; 14(3):608-613. PubMed ID: 29893327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinically relevant HIF-1α-dependent metabolic reprogramming in oropharyngeal squamous cell carcinomas includes coordinated activation of CAIX and the miR-210/ISCU signaling axis, but not MCT1 and MCT4 upregulation.
    Sáenz-de-Santa-María I; Bernardo-Castiñeira C; Secades P; Bernaldo-de-Quirós S; Rodrigo JP; Astudillo A; Chiara MD
    Oncotarget; 2017 Feb; 8(8):13730-13746. PubMed ID: 28099149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial.
    Janning M; Müller V; Vettorazzi E; Cubas-Cordova M; Gensch V; Ben-Batalla I; Zu Eulenburg C; Schem C; Fasching PA; Schnappauf B; Karn T; Fehm T; Just M; Kühn T; Holms F; Overkamp F; Krabisch P; Rack B; Denkert C; Untch M; Tesch H; Rezai M; Kittel K; Pantel K; Bokemeyer C; Loibl S; von Minckwitz G; Loges S
    Int J Cancer; 2019 Aug; 145(3):857-868. PubMed ID: 30694523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1alpha, GLUT1, and CAIX.
    Chen CL; Chu JS; Su WC; Huang SC; Lee WY
    Virchows Arch; 2010 Jul; 457(1):53-61. PubMed ID: 20526721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
    Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
    Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAIX forms a transport metabolon with monocarboxylate transporters in human breast cancer cells.
    Ames S; Andring JT; McKenna R; Becker HM
    Oncogene; 2020 Feb; 39(8):1710-1723. PubMed ID: 31723238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycolysis-related protein expression in thyroid cancer.
    Nahm JH; Kim HM; Koo JS
    Tumour Biol; 2017 Mar; 39(3):1010428317695922. PubMed ID: 28347233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose metabolism in NSCLC is histology-specific and diverges the prognostic potential of 18FDG-PET for adenocarcinoma and squamous cell carcinoma.
    Schuurbiers OC; Meijer TW; Kaanders JH; Looijen-Salamon MG; de Geus-Oei LF; van der Drift MA; van der Heijden EH; Oyen WJ; Visser EP; Span PN; Bussink J
    J Thorac Oncol; 2014 Oct; 9(10):1485-93. PubMed ID: 25170642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The basal epithelial marker P-cadherin associates with breast cancer cell populations harboring a glycolytic and acid-resistant phenotype.
    Sousa B; Ribeiro AS; Nobre AR; Lopes N; Martins D; Pinheiro C; Vieira AF; Albergaria A; Gerhard R; Schmitt F; Baltazar F; Paredes J
    BMC Cancer; 2014 Oct; 14():734. PubMed ID: 25269858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4.
    Pinheiro C; Miranda-Gonçalves V; Longatto-Filho A; Vicente AL; Berardinelli GN; Scapulatempo-Neto C; Costa RF; Viana CR; Reis RM; Baltazar F; Vazquez VL
    Cell Cycle; 2016 Jun; 15(11):1462-70. PubMed ID: 27105345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients.
    Goorts B; van Nijnatten TJ; de Munck L; Moossdorff M; Heuts EM; de Boer M; Lobbes MB; Smidt ML
    Breast Cancer Res Treat; 2017 May; 163(1):83-91. PubMed ID: 28205044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.